139 related articles for article (PubMed ID: 22699203)
1. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.
Stepanski EJ; Reyes C; Walker MS; Satram-Hoang S; Leon L; Wojtowicz-Praga S; Miller PJ; Houts AC; Schwartzberg LS
Pancreas; 2013 Jan; 42(1):32-6. PubMed ID: 22699203
[TBL] [Abstract][Full Text] [Related]
2. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
Westphalen CB; Kukiolka T; Garlipp B; Hahn L; Fuchs M; Malfertheiner P; Reiser M; Kütting F; Heinemann V; Beringer A; Waldschmidt DT
BMC Cancer; 2020 Feb; 20(1):155. PubMed ID: 32093649
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Van Cutsem E; Li CP; Nowara E; Aprile G; Moore M; Federowicz I; Van Laethem JL; Hsu C; Tham CK; Stemmer SM; Lipp R; Zeaiter A; Fittipaldo A; Csutor Z; Klughammer B; Meng X; Ciuleanu T
Br J Cancer; 2014 Nov; 111(11):2067-75. PubMed ID: 25247318
[TBL] [Abstract][Full Text] [Related]
4. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
6. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Aranda E; Manzano JL; Rivera F; Galán M; Valladares-Ayerbes M; Pericay C; Safont MJ; Mendez MJ; Irigoyen A; Arrivi A; Sastre J; Díaz-Rubio E
Ann Oncol; 2012 Jul; 23(7):1919-25. PubMed ID: 22156621
[TBL] [Abstract][Full Text] [Related]
7. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
8. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Wacker B; Nagrani T; Weinberg J; Witt K; Clark G; Cagnoni PJ
Clin Cancer Res; 2007 Jul; 13(13):3913-21. PubMed ID: 17606725
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
[TBL] [Abstract][Full Text] [Related]
12. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
[TBL] [Abstract][Full Text] [Related]
13. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Wu YL; Zhou C; Liam CK; Wu G; Liu X; Zhong Z; Lu S; Cheng Y; Han B; Chen L; Huang C; Qin S; Zhu Y; Pan H; Liang H; Li E; Jiang G; How SH; Fernando MCL; Zhang Y; Xia F; Zuo Y
Ann Oncol; 2015 Sep; 26(9):1883-1889. PubMed ID: 26105600
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Yang ZY; Yuan JQ; Di MY; Zheng DY; Chen JZ; Ding H; Wu XY; Huang YF; Mao C; Tang JL
PLoS One; 2013; 8(3):e57528. PubMed ID: 23472089
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
[TBL] [Abstract][Full Text] [Related]
16. Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice.
Diaz Beveridge R; Alcolea V; Aparicio J; Segura Á; García J; Corbellas M; Fonfría M; Giménez A; Montalar J
JOP; 2014 Jan; 15(1):19-24. PubMed ID: 24413779
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Haas M; Siveke JT; Schenk M; Lerch MM; Caca K; Freiberg-Richter J; Fischer von Weikersthal L; Kullmann F; Reinacher-Schick A; Fuchs M; Kanzler S; Kunzmann V; Ettrich TJ; Kruger S; Westphalen CB; Held S; Heinemann V; Boeck S
Eur J Cancer; 2018 May; 94():95-103. PubMed ID: 29549862
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
[TBL] [Abstract][Full Text] [Related]
19. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Assenat E; Mineur L; Mollevi C; Lopez-Crapez E; Lombard-Bohas C; Samalin E; Portales F; Walter T; de Forges H; Dupuy M; Boissière-Michot F; Ho-Pun-Cheung A; Ychou M; Mazard T
Int J Cancer; 2021 Feb; 148(3):682-691. PubMed ID: 33405269
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Saif MW
Clin Adv Hematol Oncol; 2008 Mar; 6(3):191-199. PubMed ID: 18391918
[No Abstract] [Full Text] [Related]
[Next] [New Search]